Vimarsana
Biggest News Aggregation in the World

Page 40 - Cm Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cm Management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cm Management Today - Breaking & Trending Today

Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Drops By 17.9% - Vimarsana News

Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Drops By 17.9%

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) was the target of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 30,800 shares, a decline of 17.9% from the February 28th total of 37,500 shares. Approximately 0.4% of the shares of the company are sold […]

DURECT Co. (NASDAQ:DRRX) Expected to Announce Quarterly Sales of $2.43 Million - Vimarsana News

DURECT Co. (NASDAQ:DRRX) Expected to Announce Quarterly Sales of $2.43 Million

Analysts expect that DURECT Co. (NASDAQ:DRRX – Get Rating) will post sales of $2.43 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for DURECT’s earnings, with estimates ranging from $2.00 million to $2.85 million. DURECT reported sales of $2.21 million during the same quarter last year, which would indicate […]

Femasys (NASDAQ:FEMY) Receives New Coverage from Analysts at HC Wainwright - Vimarsana News

Femasys (NASDAQ:FEMY) Receives New Coverage from Analysts at HC Wainwright

HC Wainwright started coverage on shares of Femasys (NASDAQ:FEMY – Get Rating) in a research report released on Thursday, MarketBeat.com reports. The firm issued a buy rating and a $8.00 price target on the stock. Separately, Zacks Investment Research upgraded shares of Femasys from a hold rating to a buy rating and set a $4.00 […]

Zacks: Brokerages Expect Cytosorbents Co. (NASDAQ:CTSO) Will Post Quarterly Sales of $9.84 Million - Vimarsana News

Zacks: Brokerages Expect Cytosorbents Co. (NASDAQ:CTSO) Will Post Quarterly Sales of $9.84 Million

Wall Street brokerages expect Cytosorbents Co. (NASDAQ:CTSO – Get Rating) to report sales of $9.84 million for the current quarter, according to Zacks. Five analysts have made estimates for Cytosorbents’ earnings. The highest sales estimate is $10.30 million and the lowest is $9.16 million. Cytosorbents posted sales of $10.60 million during the same quarter last […]

$52.83 Million in Sales Expected for Travere Therapeutics, Inc. (NASDAQ:TVTX) This Quarter - Vimarsana News

$52.83 Million in Sales Expected for Travere Therapeutics, Inc. (NASDAQ:TVTX) This Quarter

Equities analysts predict that Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Rating) will post sales of $52.83 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Travere Therapeutics’ earnings. The highest sales estimate is $55.13 million and the lowest is $49.30 million. Travere Therapeutics posted sales of $47.41 million […]